Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: SPRINTEC — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SPRINTEC (norgestimate and ethinyl estradiol) from Teva Pharmaceuticals USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPRINTEC (NORGESTIMATE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for SPRINTEC (NORGESTIMATE AND ETHINYL ESTRADIOL)